Health Yuan: Achieve revenue of 15.216 billion yuan by 2025, with more than ten core products already advanced to Phase II clinical trials and subsequent stages.

LightningPacketLoss · 2026-04-05T15:51:11+00:00

Health Yuan Pharmaceutical achieved an operating revenue of 15.216 billion yuan, a net profit of 1.336 billion yuan, and a net cash flow of 3.892 billion yuan in 2025, representing a year-on-year increase of 7.03%. Core products such as Marcipiravir capsules have been approved and advanced to Phase II clinical trials, with a clear strategic layout.

LightningPacketLoss

2026-04-05 15:51:11

Abstract generation in progress

On March 31, Sinopharm Group Co., Ltd. disclosed its 2025 annual report. In 2025, the company achieved operating revenue of 15.22B yuan. Net profit attributable to shareholders of the listed company was 1.34B yuan; after deducting non-recurring gains and losses, attributable net profit was 1.31B yuan, maintaining a steady and sound level. Net cash flow from operating activities reached 3.89B yuan, up 7.03% year over year.

The announcement said that in 2025, Mapa Cice Vir Suave Capsules (Yi Likang) were approved for listing, and more than ten core products have been advanced smoothly to Phase II clinical trials and subsequent stages. Its strategic deployment in key tracks such as respiratory care, anti-infection, and pain relief is becoming even clearer.

(Health Yuan announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes